Episodit
-
In this episode of the DTx Podcast, Eugene Borukhovich sits down with Mike Pace, CEO and founder of PalmHealthCo, to delve into the latest developments and insights from the DTx industry from 2023 and to discuss what may be in store for 2024.
Eugene and Mike cover various aspects of the DTx landscape, including the growing importance of FDA authorizations, the shift towards non-prescription solutions, and the maturation of the industry into operations and pricing.
Learn more about the impact of FDA authorizations on scalability in the US healthcare system, the strategic integration of digital therapeutics with virtual care models, market consolidation, and the effects of decreased venture funding on the industry.
1. [04:00] What has the industry learned from Pear Therapeutics' initial growth and scaling and, ultimately, its bankruptcy?
2. [10:45] Mike mentions the importance of FDA authorizations for scalability in the US healthcare system. How does he foresee potential FDA approvals shaping the landscape for digital therapeutics in the near future?
3. [15:20] PalmHealthCo has been involved in integrating DTX with virtual care and pushing for a virtual first go-to-market model. How has this approach impacted their journey and success in the DTx space, and what are the potential implications for the industry as a whole?
4. [20:10] What is the importance of high-quality clinical evidence for achieving permanent listing under regulatory laws? How critical is this evidence generation for the future of digital therapeutics, and what challenges does Mike anticipate in this regard?
5. [25:40] Considering the rise of aggregators in the healthcare industry influencing the market for digital therapeutics, what strategies can DTx companies employ to navigate this evolving landscape?
6. [30:15] With the current state of venture funding and market consolidation in digital health, what advice does Mike have for startups in terms of maintaining a focus on positively impacting patients and families while navigating the industry's challenges?
Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders.
Guest Links and Resources:
Connect with Mike Pace on LinkedIn
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode of the DTx Podcast, Eugene Borukhovich hosts Philip Heimann, CEO of Vivira, a prominent player in the DTx landscape in Germany.
"The genesis of Vivira was the need for personalized movement therapy - we wanted to provide people with a solution that was made just for them," says Philip.
This necessity led to the development of an innovative digital therapeutic solution that has made a significant impact in the market.
Eugene and Philip dive into the profound impact of the DiGA law in Germany, passed in 2019, on Vivira's market growth. This legislation enabled general reimbursement and physician involvement in prescribing the app, marking a pivotal turning point for the company and the broader DTx landscape in Germany.
In addition, Philip sheds light on the challenges faced by DTx startups in understanding the market complexities and securing suitable funders. He stresses the importance of selecting investors who can offer long-term support and emphasizes the significance of focusing on long-term goals and building high-value companies.
1. [05:30] What challenges did Vivira face in the early stages, being almost exclusively angel-funded, and how did this contribute to the development of their DTx solution?
2. [10:45] What pivotal role has the DiGA law played in enabling Viveira's growth in the market, and what are the implications of this legislation for other DTx companies in Germany?
3. [15:20] How has Vivira's approach of not starting in the direct-to-consumer market and focusing on the DIGA prescription model influenced its journey and success in the DTx space?
4. [20:10] What is the significance of high-quality clinical evidence, particularly RCT studies, for achieving permanent listing under the DiGA law?
5. [25:40] What are the challenges and potential solutions regarding the activation of digital therapies prescribed by doctors?
6. [30:15] As a serial entrepreneur, what critical advice does Philip have for DTX startups in navigating the complexities of the market and choosing investors?
Join us on the DTx Podcast for valuable insights into the world of digital therapeutics, covering topics from legislative impacts to entrepreneurial advice. Subscribe now to stay updated on the latest episodes and continue exploring the dynamic realm of DTx.
Guest Links and Resources:
Connect with Phillip Heimann on LinkedIn
Visit Vivira
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
Puuttuva jakso?
-
In this episode, we hear from Josh Sackman, President and Co-founder of AppliedVR. AppliedVR, in their own words, provide virtual reality-based treatments that represent a comprehensive approach to chronic pain that empowers patients with accessible digital tools self-managed in their own home.
In this episode, we cover:
The origin story of AppliedVR
Transitioning from an app store for health VR to focus pain management market
Patient experience and the pain management pipeline
Funding journey and key funding milestones
The scientific hypothesis of "mind over matter" behind AppliedVR's approach and evidence generation journey
The FDA approval process for AppliedVR and lessons learned for entrepreneurs.
AppliedVR's current business hypothesis and scaling plan
Market channels and scaling VR
Guest Links and Resources:
Connect with Josh Sackman on LinkedIn
Visit www.appliedvr.io
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this replay episode, we hear from Sylvain Piquet, COO and Co-founder of Five Lives, the app that leverages the new science of brain aging, neuroplasticity, and cognitive reserve to help people improve their brain health and prevent cognitive decline and dementia.
In this episode, we cover:
The origin story of Five Lives and the motivation behind focusing on dementia and cognitive decline.
The demographics benefitting from using Five Lives
Gamifying behaviour change
Evidence generation and funding journey
The advantages of direct-to-consumer distribution through the app store
How digital therapeutics can fit within the NHS
The challenges of implementing DTx across UK, French, and German markets
Guest Links and Resources:
Connect with Sylvain Piquet on LinkedIn
Visit www.fivelives.health
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In honor of Gift of Sight month we're replaying this insightful episode with Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.
Topics include:
The background to Dopavision
The pediatric Myopia vs adult Myopia markets
Patient experience using Dopavision
Changes to clinical trials and the mechanism of action
Plans for commercialization
Potential future applications to other ophthalmological conditions and neurological conditions
The future of OTC vs Rx
Guest Links and Resources:
Connect with Mark Wuttke on LinkedIn
Visit Dopavision
Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Vijay Ravindran, founder and CEO of Floreo. Floreo allows therapy to be more engaging and happen anywhere, assisting people in practicing critical social skills at their own pace through immersive experiences, starting with adolescent Autism spectrum disorder.
In this episode, we cover:
The founding story of Floreo
Market for autism and neurodiversity
The child and caregiver experience using Floreo
Funding journey and key milestones
User and caregiver experience using Floreo
Scientific hypothesis and evidence generation journey
Scaling virtual reality in healthcare
Guest Links and Resources:
Connect with Vijay Ravindran on LinkedIn
Visit floreovr.com
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
We're seeing a broader consolidation of digital health solutions this year to bring together the amazing talent and the scientifically validated assets to drive scale in the market and improve unit economics. On the heels of last week's announcement of the merger between Fern Health and BehaVR tune into this replay episode to hear Eugene Borukhovich's conversation with Aaron Gani, Founder and CEO of BehaVR. BehaVR translates proven science into immersive and engaging XR therapeutics for mental and behavioral health.
In this episode, we cover:
Origin Story: Aaron Gani shares the origin story of BehaVR, starting from its inception in 2016 and the inspiration behind creating immersive XR therapeutics for mental and behavioral health.
Funding Journey and Milestones: Walk through BehaVR's funding journey, uncovering the key milestones achieved with each funding round and how it has shaped the company's growth and impact in the digital therapeutics landscape.
Patient Journey Using VR: Gain insights into the end customer experience offered by BehaVR, highlighting the effectiveness of immersive therapeutics in supporting mental well-being.
Scientific Hypothesis and Evidence Generation: Explore the hypothesis that BehaVR is built upon and learn how their evidence generation journey is proving the effectiveness of their immersive XR therapeutics, showcasing the power of mind-body connections.
Merging with OxfordVR and FDA Approval: Discover the decision-making process behind BehaVR's merger with OxfordVR and their journey towards FDA approval.
Business Hypothesis and Scaling Plan: Delve into BehaVR's current business hypothesis and explore their scaling plan.
Partnership with Sumitomo Dainippon: Aaron expands on BehaVR's partnership with Sumitomo Dainippon and discusses the commercial arrangement that led to this collaboration.
Access to Care: Explore the accessibility of virtual reality therapy and its role in improving access to care for patients.
Pear Therapeutics and the Future of PDTs: Aaron shares his thoughts on Pear Therapeutics and discusses the future of Prescription Digital Therapeutics (PDTs), providing insights into the evolving landscape of digital therapeutics and its potential to revolutionize mental health care.
Guest Links and Resources:
Connect with Aaron Gani on LinkedIn
Visit BehaVR
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from, Rich Brancaccio, Chief Innovation Officer of Revibe Technologies, and Lindsay Ayearst, Chief Scientific Officer of Revibe Technologies.
In their own words, Revibe is a digital therapeutics company fusing behavioral science with technology and currently developing a new digital therapy for ADHD.
In this episode, we cover:
Founding story and funding milestones
Child and caregiver experience using Revibe
Quantifying attention & capturing focus data
Evidence generation journey & clinical endpoints
The ADHD market choice to focus on adolescent ADHD
Lessons learned from the first wave of similar products and companies
OTC vs PDT
Guest Links and Resources:
Connect with Lindsay Ayearst on LinkedIn
Connect with Rich Brancaccio on LinkedIn
Visit www.revibetech.com
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics.
Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question.
Guest Links and Resources:
Connect with Brent Vaughan: LinkedIn
Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Chan Yoon, MD, CEO of EverEx. EverEx is revolutionizing musculoskeletal rehabilitation with cutting edge AI, pose estimation technology, and evidence based treatments.
In this episode, we cover:
Insights into Digital Health in South Korea
The EverEx creation journey
The musculoskeletal health market in South Korea
Funding journey and challenges in the market
Reimbursement environment in South Korea
Entering the US Market with the product EverEx Rehab
Clinical trials and patient experience using EverEx products
Guest Links and Resources:
Connect with Chan Yoon on LinkedIn
Visit Everex.kr
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that’s exactly what his company is called: Better Therapeutics.
Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to “help people change some of those core beliefs, which then directly influence what we do on a day to day basis.”
And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors.
Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions.
In this episode, we cover:
Patient experience using digital therapeutics for type 2 diabetes
Nutritional CBT – Better Therapeutics innovative new form of Cognitive Behavioral Therapy
Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps
What’s next in the Better Therapeutics pipeline and how these decisions are made
The future of Digital Therapeutic infrastructure
Guest Links and Resources:
Connect with Mark Berman on LinkedIn | Twitter
Visit bettertx.com
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Francesca Wuttke, Founder and CEO of Nen who is focusing on building prescription digital therapeutic at a cross-section of pediatrics, pain with an initial focus in oncology.
In this episode, we cover:
The background to nen and naming the company
Gamifying CBT for treating children's pain
Targeting the psychological aspects of pain
Treating unmet needs in oncology
Patient and parent experience
Clinical evidence generation and PDT
Business hypothesis, market entry, pricing and reimbursements
Guest Links and Resources:
Connect with Francesca Wuttke on LinkedIn
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
Curio has announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial demonstrating that MamaLift Plus has met its efficacy endpoints. This is a significant step towards providing better support for mothers during a crucial time.
In this Replay episode we hear from Shailja Dixit, CEO of Curio. In their own words: 'Curio is a Digital Therapeutics company with tailor-made Cognitive Behavioral Therapy programs for Women across the cycle of life – encompassing age groups, physiological conditions and social settings'.
Topics include:
The Founding Story of Curio
Using Digital to Destigmatize Mental Health Support
User experience of the MamaLift product
Combining methods of Cognitive Behavioural Therapy, Interpersonal Therapy and Behavioural Activation Therapy
PDT vs Physician recommended DTx
Guest Links and Resources:
Connect with Shailja Dixit on LinkedIn
Visit https://www.curiodigitaltx.com/
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Sponsors: Akili | LSI | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this special feed drop hear Eugene Borukhovich in conversation with Pharmaphorum Editor in Chief Jonah Comstock discussing what they saw and heard at DTx East in Boston.
This year the digital therapeutics space took a hit with the downfall of Pear Therapeutics, one of the most well-known of the industry’s still-active pioneers. Combined with Akili Interactive’s hard pivot to OTC , some in the industry are wondering whether standalone prescription digital therapeutics are a failed experiment.
Pharmaphorum Links and Resources:
Connect with Jonah Comstock on LinkedIn
Visit pharmaphorum.com
Episode Write Up
Pharmaphorum Podcast
DTx Podcast Links and Resources::
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.
Topics include:
The background to Dopavision
The pediatric Myopia vs adult Myopia markets
Patient experience using Dopavision
Changes to clinical trials and the mechanism of action
Plans for commercialization
Potential future applications to other ophthalmological conditions and neurological conditions
The future of OTC vs Rx
Guest Links and Resources:
Connect with Mark Wuttke on LinkedIn
Visit Dopavision
Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Andrew Jenkinson and Niall O'Driscol, CEO's and Co-founders of vStream. vStream's primary focus is on the creation of compelling and engaging patient-centric experiences. Specializing in virtual reality, augmented reality, mixed reality, 360 video, immersive experiences, and digital installations
Topics include:
The background to vStream and the product ShineVR
The funding journey
Competition and the overall market in virtual reality
Patient experience using ShineVR incorporating proven CBT techniques in a number of different spaces
Scientific hypothesis and evidence generation process
The proposition to employers for for corporate wellness
Scaling plan and future pipeline
Insights from a patient using ShineVR
Guest Links and Resources:
Connect with Niall O'Driscoll on LinkedIn
Connect with Andrew Jenkinson on LinkedIn
Visit vStream
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
If you’ve been keeping up with the news you’ll know that since March this year, Kranus Edera has been permanently listed as a digital health application by the Federal Institute for Drugs and Medical Devices. But the journey did not stop there. Last week Kranus Health achieved another milestone: successful price negotiations with the GKV-Spitzenverband, which is in charge of negotiating the reimbursement amount for new medications from pharmaceutical manufacturers. Kranus Edera has now secured one of the highest permanent reimbursement prices ever recorded for a DiGA in Germany: €235 (incl. VAT).
To provide some context for this exciting development we’re revisiting our episode with Jens Noertershaeuser, Founder & Co-CEO of Kranus Health. In their own words, Kranus Health’s mission is to revolutionize men's health by providing innovative and accessible healthcare solutions. As one of only 10 companies with a permanent approval, Kranus Edera is the only the first digital health app (DiGA) for the treatment of erectile dysfunction.
In this episode, we cover:
The background to Kranus Health
The focus on men’s health and erectile dysfunction as a flagship product
Products in development and the future of Kranus Health
The funding journey
Patient experience using the product
Evidence generation and the DiGA process
Insurance company reimbursment
Guest Links and Resources:
Connect with Jens Noertershaeuser on LinkedIn
Visit kranushealth.com
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Meri Beckwith, Co-founder of Lindus Health. In their own words, Lindus delivers end to end clinical trials for health tech and biotech pioneers.
Topics include:
The background and inception story of Lindus Health
Lindus Health's place in the value chain
Achieving key funding milestones in a difficult market enviroment
The unique aspects of clinical trials for DTx
Pharmaceutical clients in the DTx market
The future for clinical trials and digitization
Guest Links and Resources:
Connect with Meri Beckwith on LinkedIn
Visit Lindus Health
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
In this episode, we hear from Susa Monacelli, General Manager at Propeller Health. In their own words Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life.
Topics include:
The background to Propeller Health and the ResMed umbrella
The original business hypothesis of ResMed and how this has evolved
Patient experience using Propeller Health
Differentiating propositions to health system, pharma and payers
DTx vs. Disease Management 2.0
The future of prescription digital therapeutics
Partnerships with health systems vs other routes to patient access
Challenges holding the digital health industry back
Guest Links and Resources:
Connect with Susa Monacelli on LinkedIn
Visit Propeller Health
Episode PDF
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram -
Have you heard? On August 22, Mahana Therapeutics announced a distribution and marketing partnership with Bayer’s consumer health division. This partnership unites Mahana’s proficiency in digital therapeutic advancement with Bayer’s commitment to empowering individuals through cutting-edge digital solutions, all aimed at enabling greater personal health control. The full press release is linked below.
In light of this, we’re bringing you this replay episode with Simon Levy, CEO and Co-founder, and Ann Montgomery, Chief Product Officer at Mahana.
In their own words, Mahana develops digital treatments for people living with chronic health conditions, and their first treatment, Mahana for IBS, is now available as an FDA-cleared app.
In this episode, we cover:
The founding story and funding journey of Mahana
Complexities of the end to end patient experience
The freemium model and how that translates into a PDT
Evidence generation and FDA clearance process
Scaling plans for PDTs
Guest Links and Resources:
Press Release about the Mahana and Bayer partnership
Connect with Simon Levy on LinkedIn
Connect with Ann Montgomery on LinkedIn
Visit Mahana.com
Host Links:
Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram - Näytä enemmän
